Thyromimetics: a review of recent reports and patents (2004 – 2009)

Bibliography

• Greenspan FS, Strewler GJ. Basic & clinical endocrinology. 5th edition. Appleton & Lange: Stamford; 1997
   Google Scholar
• Mangelsdorf DJ, Thummel C, Beato M, The nuclear receptor superfamily: the second decade. Cell 1996;83:835-9
   Google Scholar
• Lazar MA. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocrinol Rev 1993;14:184-93
   PubMed Web of Science ®Google Scholar
• Johansson C, Vennström B, Thorén P. Evidence that decreased heart rate in thyroid hormone receptor-alpha1-deficient mice is an intrinsic defect. Am J Physiol 1998;275:R640-6
   PubMed Web of Science ®Google Scholar
• Cheng S-Y. Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord 2000;1:9-18
   PubMedGoogle Scholar
• Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001;81:1097-142
   PubMed Web of Science ®Google Scholar
• Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med 2003;348:2646-55
   PubMed Web of Science ®Google Scholar
• Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-17
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Frishman WH. Thyroid hormone and cardiovascular disease. Am Heart J 1998;135:187-96
   PubMedGoogle Scholar
• Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-9
   PubMed Web of Science ®Google Scholar
• Malm J. Therapeutic thyroid hormone ligand patents 1998 – 2003. Expert Opin Ther Pat 2004;14:1169-83
   Web of Science ®Google Scholar
• Goslings B, Schwartz HL, Dillmann W, Comparison of the metabolism and distribution of L-triiodothyronine and triiodothyroaeetic acid in the rat: a possible explanation of differential hormonal potency. Endocrinology 1976;98:666-75
   PubMed Web of Science ®Google Scholar
• Beck-Peccoz P, Sartorio A, De Medici C, Dissociated thyromimetic effects of 3,5,3′-triiodothyroacetic acid (Triac) at the pituitary and peripheral tissue levels. J Endocrinol Invest 1988;11:113-18
   PubMedGoogle Scholar
• Messier N, Laflamme L, Hamann G, Langlois MF. In vitro effect of Triac on resistance to thyroid hormone receptor mutants: potential basis for therapy. Mol Cell Endocrinol 2001;174:59-69
   Google Scholar
• Underwood AH, Emmett JC, Ellis D, A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature 1986;324:425-9
   PubMed Web of Science ®Google Scholar
• Leeson PD, Ellis D, Emmett JC, Thyroid hormone analogs. Synthesis of 3′-substituted 3,5-diiodo-L-thyronines and quantitative structure–activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart. J Med Chem 1988;31:37-54
   Google Scholar
• Yokoyama N, Walker GN, Main AJ, Synthesis and structure–activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine. J Med Chem 1995;38:695-707
   PubMed Web of Science ®Google Scholar
• Ye L, Li Y-L, Mellström K, Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor alpha1. J Med Chem 2003;46:1580-8
   Google Scholar
• Chiellini G, Apriletti JW, Yoshihara HA, A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 1998;5:299-306
   PubMed Web of Science ®Google Scholar
• Wagner RL, Huber BR, Shiau AK, Hormone selectivity in thyroid hormone receptors. Mol Endocrinol 2001;15:398-410
   PubMed Web of Science ®Google Scholar
• Bleicher L, Aparicio R, Nunes FM, Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms. BMC Struct Biol 2008;8:8
   PubMedGoogle Scholar
• Ebisawa M, Inoue N, Fukasawa H, Thiazolidinediones with thyroid hormone receptor agonistic activity. Chem Pharm Bull 1999;47:1348-50
   PubMedGoogle Scholar
• Dow RL, Schneider SR, Paight ES, Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRalpha subtype-selective thyromimetics. Bioorg Med Chem Lett 2003;13:379-82
   Google Scholar
• Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimentional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000;21:381-8
   PubMed Web of Science ®Google Scholar
• Wagner RL, Apriletti JW, McGrath ME, A structural role for hormone in the thyroid hormone receptor. Nature 1995;378:690-7
   PubMed Web of Science ®Google Scholar
• Baxter JD, Goede P, Apriletti JW, Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology 2002;14:517-24
   Google Scholar
• Chiellini G, Nguyen N-H, Apriletti JW, Synthesis and biological activity of novel thyroid hormone analogues: 5′-aryl substituted GC-1 derivatives. Bioorg Med Chem 2002;10:333-46
   PubMed Web of Science ®Google Scholar
• Nguyen N-H, Apriletti JW, Cunha Lima ST, Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 2002;45:3310-20
   PubMed Web of Science ®Google Scholar
• Nguyen N-H, Apriletti JM, Baxter JD, Scanlan TS. Hammett analysis of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists. J Am Chem Soc 2005;127:4599-608
   Google Scholar
• Shah V, Nguyen P, Nguyen N-H, Complex action of thyroid hormone receptor antagonist NH-3 on gene promoters in different cell lines. Mol Cell Endocrinol 2008;296:69-77
   Google Scholar
• Yoshihara HA, Apriletti JW, Baxter JD, Scanlan TS. A designed antagonist of the thyroid hormone receptor. Bioorg Med Chem Lett 2001;11:2821-5
   Google Scholar
• Bakker O, van Beeren HC, Wiersinga WM. Desethylamiodarone is a noncompetitive inhibitor of the binding of thyroid hormone to the thyroid hormone beta 1-receptor protein. Endocrinology 1994;134:1665-70
   PubMed Web of Science ®Google Scholar
• Carlsson B, Singh BN, Temciuc M, Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amidarone. J Med Chem 2002;45:623-30
   PubMed Web of Science ®Google Scholar
• Ocasio CA, Scanlan TS. Design and characterization of a thyroid hormone receptor alpha (TRalpha)-specific agonist. ACS Chem Biol 2006;1:585-93
   Google Scholar
• Lim W, Nguyen N-H, Yang HY, A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J Biol Chem 2002;277:35664-70
   PubMed Web of Science ®Google Scholar
• Furlow JD, Yang HY, Hsu M, Induction of larval tissue resorption in Xenopus laevis tadpoles by thyroid hormone receptor agonist GC-1. J Biol Chem 2004;279:26555-62
   Google Scholar
• Cadila Healthcare Limited. Imidazolidinediones and related compounds as selective TR-beta 1 agonist and their preparation, pharmaceutical compositions and use in the treatment of dyslipidemia and obesity. WO2007132475; 2007
   Google Scholar
• Hashimoto A, Shi Y, Drake K, Koh JT. Design and synthesis of complementing ligands for mutant thyroid hormone receptor TRalpha(R320H): a tailor-made approach toward the treatment of resistance to thyroid hormone. Bioorg Med Chem 2005;13:3627-39
   Google Scholar
• Haning H, Mueller U, Schmidt G, Novel heterocyclic thyromimetics. Part 2. Bioorg Med Chem Lett 2007;17:3992-6
   Google Scholar
• Komatsu T, Hirano T, Songkram C, Novel thyroid hormone receptor antagonists with an N-alkylated diphenylamine skeleton. Bioorg Med Chem 2007;15:3115-26
   Google Scholar
• Tokyo medical and dental university. Thyroid hormone receptor antagonists containing thiazolidinedione compounds and pharmaceuticals containing them. JP2008189620; 2008
   Google Scholar
• Bristol-Myers Squibb Company. Cycloalkyl containing anilide ligands for the thyroid receptor. WO2004066929; 2004
   Google Scholar
• Garg N, Li Y-L, Collazo AMG, Thyroid receptor ligands. Part 8: thyromimetics derived from N-acylated-a-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141. Bioorg Med Chem Lett 2007;17:4131-4
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Aniline-derived ligands for the thyroid receptor. WO2001060784; 2001
   Google Scholar
• Kissei Pharmaceutical Co. Ltd. Malonilic acid derivatives, medicinal compositions containing the same and use thereof. WO2001085670; 2001
   Google Scholar
• Bristol-Myers Squibb Company. Substituted anilide ligands for the thyroid receptor. WO2004067482; 2004
   Google Scholar
• Berkenstam A, Kristensen J, Mellstrom K, The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008;105:663-7
   PubMed Web of Science ®Google Scholar
• Karo Bio AB. Bristol-Myers Squibb Company. Stable oral pharmaceutical composition containing thyroid hormone receptor agonists. WO2007110226; 2007
   Google Scholar
• Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics. WO2005051298; 2005
   Google Scholar
• Boyer SH, Jiang H, Jacintho JD, Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J Med Chem 2008;1:7075-93
   Google Scholar
• Erion MD, Cable EE, Ito BR, Targeting thyroid hormone receptor-alpha agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007;104:15490-5
   PubMed Web of Science ®Google Scholar
• Bayer Healthcare AG. Benzofuran derivatives. WO02079181; 2002
   Google Scholar
• Karo Bio AB. Idol derivatives as new thyroid receptor agonist ligands and methods. WO2004018421; 2004
   Google Scholar
• Collazo AMG, Koehler KF, Garg N, Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor alpha. Bioorg Med Chem Lett 2006;16:1240-4
   Google Scholar
• Borngraeber S, Budny M-J, Chiellini G, Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc Natl Acad Sci USA 2003;100:15358-63
   PubMed Web of Science ®Google Scholar
• Hangeland JJ, Doweyko AM, Dejneka T, Thyroid receptor ligands. Part 2: thyromimetics with improved selectivity for the thyroid hormone receptor beta. Bioorg Med Chem Lett 2004;14:3549-53
   Google Scholar
• Bristol-Myers Squibb Company. Thyroid receptor ligands. WO2004093799; 2004
   Google Scholar
• Li Y-L, Litten C, Koehler KF, Thyroid receptor ligands. Part 4: 4′-amido bioisostetic ligands selective for the thyroid hormone receptor beta. Bioorg Med Chem Lett 2006;16:884-6
   Google Scholar
• Koehler K, Gordon S, Brandt P, Thyroid receptor ligands. Part 6: high affinity “direct antagonist” selective for the thyroid hormone receptor. J Med Chem 2006;49:6635-7
   Google Scholar
• Haning H, Woltering M, Mueller U, Novel heterocyclic thyromimetics. Bioorg Med Chem Lett 2005;15:1835-40
   Google Scholar
• Bayer Healthcare AG. Indoles for treating diseases that can be treated using thyroid hormones. WO0170687; 2001
   Google Scholar
• Bayer Healthcare AG. Indazoles having an action similar to that of a thyroid hormone, method for the production thereof, and their use in medicaments. WO0222586; 2002
   Google Scholar
• Karo Bio AB. Indole derivatives and their use as thyroid receptor ligands. WO2007134864; 2007
   Google Scholar
• Karo Bio AB. Heterocyclic compounds as agonists for the thyroid hormone receptor. WO2007003419; 2007
   Google Scholar
• Karo Bio AB. Novel Pharmaceutical Compositions. WO2007128492; 2007
   Google Scholar
• F. Hoffmann-La Roche AG. Pyridazinone derivatives as thyroid hormone receptor agonists. WO2007009913; 2007
   Google Scholar
• F. Hoffmann-La Roche AG. Prodrugs to thyroid hormone analogues. WO2009037172; 2009
   Google Scholar
• Koh JT. Engineering control over protein function; transcriptional control by small molecules. Chapter 3.3. In: Schreiber SL, Kapoor T, Wess G, editors, Chemical biology. (Volume 1). Wiely-VCH Verlag GmbH & Co. KGaA: Weinheim; 2007
   Google Scholar
• Ye H, O'Reilly KE, Koh JT. A subtype-selective thyromimetic designed to bind a mutant thyroid hormone receptor implicated in resistance to thyroid hormone. J Am Chem Soc 2001;123:1521-2
   Google Scholar
• Shi Y, Ye H, Link KH, Mutant-selective thyromimetics for the chemical rescue of thyroid hormone receptor mutants associated with resistance to thyroid hormone. Biochemistry 2005;44:4612-26
   Google Scholar
• Nomura Y, Nagaya T, Tsukaguchi H, Amino acid substitutions of thyroid hormone receptor-beta at codon 435 with resistance to thyroid hormone selectively alter homodimer formation. Endocrinology 1996;137:4082-6
   Google Scholar
• Ando S, Sarlis NJ, Oldfield EH, Yen PM. Somatic mutation of TRalpha can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 2001;86:5572-6
   PubMed Web of Science ®Google Scholar
• Hassan AQ, Koh JT. A functionally orthogonal ligand-receptor pair created by targeting the allosteric mechanism of the thyroid hormone receptor. J Am Chem Soc 2006;128:8868-74
   Google Scholar
• Hassan AQ, Koh JT. Selective chemical rescue of a thyroid-hormone-receptor mutant, TRalpha(R435Y), identified in pituitary carcinoma and resistance to thyroid hormone. Angew Chem Int Ed 2008;47:7280-3
   Google Scholar
• Shibusawa N, Hashimoto K, Nikrodhanond AA, Thyroid hormone action in the absence of thyroid hormone receptor DNA-binding in vivo. J Clin Invest 2003;112:588-97
   PubMed Web of Science ®Google Scholar
• Hiroi Y, Kim- H-H, Ying H, Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 2006;103:14104-9
   PubMed Web of Science ®Google Scholar
• Scanlan TS, Suchland KL, Hart ME, 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 2004;10:638-42
   PubMed Web of Science ®Google Scholar
• The reagents of the university of California; Oregon health & science university. Thyronamine derivatives and analogs and methods of used thereof. WO2004093800; 2004
   Google Scholar
• Hedfors Å, Appelqvist T, Carlsson B, Bladh L-G, Litten C, Agback P, Grynfarb M, Koehler KF, Malm J. Thyroid receptor ligands. Part 3: design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem 2005;48:3114-17
   Google Scholar
• Karo Bio AB. Preparation of 4-benzyloxyphenylalkanoic acids and analogs as thyroid receptor antagonists for the treatment of cardiac and metabolic disorders. WO2001036365; 2001
   Google Scholar
• Karo Bio AB. Thyroid hormone receptor antagonists for cardiac and metabolic disorders II. WO2002092550; 2002
   Google Scholar
• Shiau AK, Barstad D, Radek JT, Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 2002;9:359-64
   PubMedGoogle Scholar
• Malm J, Gordon S, Brandt P, Thyroid receptor ligands. Part 7: indirect antagonists of the thyroid hormone receptor with improved affinity. Bioorg Med Chem Lett 2007;17:2018-21
   Google Scholar
• Karo Bio AB. Thyroid receptor agonists. WO2005092317; 2005
   Google Scholar
• Karo Bio AB. Novel pharmaceutical compositions comprising agonists of the thyroid hormone receptor. WO2005092316; 2005
   Google Scholar
• Hangeland JJ, Friends TJ, Doweyko AM, A new class of high affinity thyromimetics containing a phenyl-naphthylene core. Bioorg Med Chem Lett 2005;15:4579-84
   Google Scholar
• Bristol-Myers Squibb Company. Phenyl naphthol ligands for thyroid hormone receptor. US2003166724; 2003
   Google Scholar
• New York University. Driverse thyroid hormone receptor antagonists and uses thereof. WO2004103289; 2004
   Google Scholar
• Cadila Healthcare Limited. Selective TR-beta 1 agonist. WO2008062469; 2008
   Google Scholar